Scientists say study findings indicate that TC IV cells may represent a therapeutic target for the treatment of food-associated allergic and inflammatory diseases.

Researchers were able to test how viruses replicate differently across various bat species and organs using the new organoid ...

To address this challenge, CTMC has established a patient material bank, enabling early-stage process development with clinically relevant samples. This resource also supports continuous process ...

Estrogen-related receptors (ERRs) regulate muscle mitochondria in mice, revealing a new potential drug targets for metabolic diseases.

CEO Serge Saxonov, PhD, acknowledged that its R&D operation “definitely ended up being impacted in a substantial way” while sales operations were less impacted since the company reorganized its sales ...

Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows improvement from a rare metabolic disease.

TAHITI couples CRISPR with transposable elements from plants to edit cash crops such as corn and soybean with reduced ...

Imprint has raised $15 million to decode the body's immune memory for understanding chronic diseases, such as long-COVID and ...

Study in mice shows how a host-elicited factor benefits gut immunological homeostasis by selectively targeting commensal ceramide molecules.

Some of the most widely used methods include a tangential flow filter (TFF). Instead of flowing through a filter, a sample ...

Not designing with manufacturing in mind—even during early development—is a key reason fledgling biopharma companies fail.

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing facility will be ...